Navigation Links
Alzheimer's drug developer lands $1.2M in venture funding

Madison, Wis. - Mithridion, Inc., a biopharmaceutical start up that is developing drugs to disrupt the progress of Alzheimer's disease, has closed an additional $1.2 million of Series A funding led by Madison's Venture Investors.

The latest round of funding brings the total equity capital raised in th......

Full article >>> s, and the continued support of WARF and Rosetta Partners.

"It's a great leap forward for our company in getting Venture Investors, a professional investment firm," Twose said. "It's not only a leap forward in terms of getting the funding, it's the quality of the investors they bring in."

The new funding will be used to advance Mithridion's drug lead, a prototype drug that will b......

Full article >>> ts discovery is based on animal models used in Alzheimer's research. "It was noted that they [the animals] did not develop the full form of Alzheimer's, which caused investors to ask why?" Neis said.

......

Full article >>>
'"/>

Source:wistechnology.com By WTN News 04/17/07


Related biology technology :

1. Biotech firm has strokes, Alzheimers in its sights
2. Mithridion wins grants for Alzheimers research
3. Alzheimers drug firm and more winners named in Wisconsin business-plan contest
4. Alzheimers drug market to hit $5.5 billion by 2009, study says
5. Marshfield study mixes DNA into electronic medical record to screen for Alzheimers
6. UW Alzheimers researchers found company; privacy law; Science Expeditions
7. Madison-based Mithridion seeks to capitalize on Alzheimers breakthrough
8. Discovery may halt progression of Alzheimers
9. Milwaukee software developer gains bottom line, loses waistline
10. Emerging game developer begins work on prototypes
11. Metavante to buy California software developer
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
(Date:6/23/2016)... , June 23, 2016   Boston ... of novel compounds designed to target cancer stemness ... has been granted Orphan Drug Designation from the ... treatment of gastric cancer, including gastroesophageal junction (GEJ) ... inhibitor designed to inhibit cancer stemness pathways by ...
(Date:6/23/2016)... Prostate Cancer Foundation (PCF) is pleased to announce 24 new Young ... cancer. Members of the Class of 2016 were selected from a pool of ... More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... In a new case ... Denmark detail how a patient who developed lymphedema after being treated for breast cancer ... could change the paradigm for dealing with this debilitating, frequent side effect of cancer ...
Breaking Biology Technology:
(Date:6/9/2016)... leader in attendance control systems is proud to announce the introduction of fingerprint attendance ... the right employees are actually signing in, and to even control the opening of ... ... ... Photo - ...
(Date:6/2/2016)... The Department of Transport Management (DOTM) of ... Dollar project, for the , Supply and Delivery ... IT Infrastructure , to Decatur ... Identity Management Solutions. Numerous renowned international vendors participated in the ... was selected for the most compliant and innovative solution. The ...
(Date:5/24/2016)... , May 24, 2016 Ampronix facilitates superior patient care by providing ...  3D medical LCD display is the latest premium product recently added to the range ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
Breaking Biology News(10 mins):